Abstract: Specified performance attributes may be used to configure machine learning transformations for ETL jobs. Performance attributes for a machine learning pipeline that applies a model to as part of a transformation for an ETL job may be used to configure a parameter in a stage of the machine learning pipeline. The configured stage may then be used when training the model. The trained machine learning pipeline may then be applied as part of a transformation operation included in an ETL job performed by the ETL system.

Abstract: Disclosed herein are therapeutic use of isoform-specific, context-permissive inhibitors of TGF?1 in the treatment of disease that involve TGF?1 dysregulation.

Abstract: Disclosed herein are immunoglobulins, such as antibodies, and antigen binding portions thereof, that specifically bind complexes of GARP-TGF?1, LTBP1-TGF?1, LTBP3-TGF?1, and/or LRRC33-TGF?1. The application also provides methods of use of these immunoglobulins for, for example, inhibiting TGF?1 activity, and treating subjects suffering from TGF?1-related disorders, such as cancer and fibrosis.

Abstract: A system and method for non-invasively applying electrical stimulation to target the olfactory bulb and olfactory mucosa. Current is delivered through an optimal montage of electrodes positioned on the lower forehead, nose bridge, and neck posterior for suppressing the progression of disorders or alleviating symptoms caused by olfactory dysfunction such as Alzheimer’s Disease, Parkinson’s Disease, Loss of Consciousness, etc. Electrode placements are proposed depending on application- for instance using only hair free zones for stimulation. This invention was made with government support under Grant R44NS092144 awarded by the National Institutes of Health. The government has certain rights in the invention.

Abstract: Disclosed herein are immunoglobulins, such as antibodies, and antigen binding portions thereof, that specifically bind complexes of GARP-TGF?1, LTBP1-TGF?1, LTBP3-TGF?1, and/or LRRC33-TGF?1. The application also provides methods of use of these immunoglobulins for, for example, inhibiting TGF?1 activity, and treating subjects suffering from TGF?1-related disorders, such as cancer and fibrosis.

Abstract: Disclosed herein are inhibitors, such as antibodies, and antigen-binding portions thereof, that selectively bind complexes of LTBP1-TGF? and/or LTBP3-TGF?. The application also provides methods of use of these inhibitors for, for example, inhibiting TGF? activation, and treating subjects suffering from TGF?-related disorders, such as fibrotic conditions. Methods of selecting a context-dependent or context-independent isoform-specific TGF? inhibitor for a subject in need thereof are also provided.

Abstract: Disclosed herein are inhibitors, such as antibodies, and antigen-binding portions thereof, that selectively bind complexes of LTBP1-TGF? and/or LTBP3-TGF?. The application also provides methods of use of these inhibitors for, for example, inhibiting TGF? activation, and treating subjects suffering from TGF?-related disorders, such as fibrotic conditions. Methods of selecting a context-dependent or context-independent isoform-specific TGF? inhibitor for a subject in need thereof are also provided.

Abstract: Disclosed herein are inhibitors, such as antibodies, and antigen-binding portions thereof, that selectively bind complexes of LTBP1-TGF? and/or LTBP3-TGF?. The application also provides methods of use of these inhibitors for, for example, inhibiting TGF? activation, and treating subjects suffering from TGF?-related disorders, such as fibrotic conditions. Methods of selecting a context-dependent or context-independent isoform-specific TGF? inhibitor for a subject in need thereof are also provided.

Abstract: Disclosed herein are monoclonal antibodies and antigen-binding fragments thereof capable of selectively inhibiting TGF?1 with high potency. Related compositions, methods and therapeutic use are also disclosed.

Abstract: Disclosed herein are inhibitors, such as antibodies, and antigen-binding portions thereof, that selectively bind complexes of LTBP1-TGF? and/or LTBP3-TGF?. The application also provides methods of use of these inhibitors for, for example, inhibiting TGF? activation, and treating subjects suffering from TGF?-related disorders, such as fibrotic conditions. Methods of selecting a context-dependent or context-independent isoform-specific TGF? inhibitor for a subject in need thereof are also provided.

Abstract: Selective inhibitors of repulsive guidance molecule C (RGMc), are described. Related methods, including methods for making, as well as therapeutic use of these inhibitors in the treatment of disorders, such as anemia, are also provided.

Abstract: Disclosed herein are monoclonal antibodies and antigen-binding fragments thereof capable of selectively inhibiting TGF?1. Related compositions, methods and therapeutic use are also disclosed.

Abstract: Disclosed herein are monoclonal antibodies and antigen-binding fragments thereof capable of selectively inhibiting TGF?1 with high potency. Related compositions, methods and therapeutic use are also disclosed.

Abstract: A device may receive information associated with an entity. The information may include a first resource and a second resource. The first resource may be associated with a first file type, and the second resource may be associated with a second file type that is different than the first file type. The first resource may be associated with a first source, and the second resource may be associated with a second source that is different than the first source. The device may extract a plurality of attributes associated with the entity based on the information. The device may implement a natural language processing technique to extract the plurality of attributes. The device may associate the plurality of attributes with a plurality of elements based on extracting the plurality of attributes. The device may provide information that identifies the plurality of elements and the plurality of attributes to permit and/or cause an action to be performed.

Abstract: A system for reconciliation comprises a determination engine to determine whether data is structured or unstructured, a data structuring engine to structure the data, and a rule extraction engine to determine relations between pairs of values of a first set and a second set of data. The system further comprises a matching engine to generate a confidence score for each pair of the values, a categorization engine to classify the pairs of values into matched pairs and unmatched pairs, a validation engine to validate matching and classification of the pairs based on a user feedback, and a learning engine to store details pertaining to the validation of the matching and the classification over a period of time. The learning engine forwards the details to the rule extraction engine and the categorization engine to determine the relations between subsequent pairs of values and classify the pairs based on the stored details.

Abstract: Disclosed herein are monoclonal antibodies and antigen-binding fragments thereof capable of selectively inhibiting TGF?1 with high potency. Related compositions, methods and therapeutic use are also disclosed.

Abstract: Disclosed herein are inhibitors, such as antibodies, and antigen-binding portions thereof, that selectively bind complexes of LTBP1-TGF? and/or LTBP3-TGF?. The application also provides methods of use of these inhibitors for, for example, inhibiting TGF? activation, and treating subjects suffering from TGF?-related disorders, such as fibrotic conditions. Methods of selecting a context-dependent or context-independent isoform-specific TGF? inhibitor for a subject in need thereof are also provided.

Abstract: Disclosed herein are inhibitors, such as antibodies, and antigen binding portions thereof, that selectively bind complexes of LTBP1-TGF?1 and/or LTBP3-TGF?1. The application also provides methods of use of these inhibitors for, for example, inhibiting TGF?1 activation, and treating subjects suffering from TGF?1-related disorders, such as fibrotic conditions. Methods of selecting a context-dependent or context-independent isoform-specific TGF?1 inhibitor for a subject in need thereof are also provided.

Abstract: Disclosed herein are LRRC33 inhibiting agents and related methods and uses thereof. More specifically, therapeutic agents for inhibiting LRRC33 effects in vivo are provided. Such agents are useful for the treatment of various disorders involving cells expressing LRRC33 or LRRC33-containing complexes on the surface of cells.

Abstract: Disclosed herein are monoclonal antibodies and antigen-binding fragments thereof capable of selectively inhibiting TGF?1 with high potency. Related compositions, methods and therapeutic use are also disclosed.